Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2025 11:54 ET | Source: NeuExcell Therapeutics

NeuExcell Therapeutics Reports Encouraging Clinical Results with World’s First In Situ Conversion Therapy for Malignant Glioma

NeuExcell’s NXL-004, first in situ conversion gene therapy, shows promising safety and efficacy in 11 GBM patients at ESMO Asia 2025
November 29, 2022 08:00 ET | Source: Helsinn Healthcare S.A.

Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia

Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano, Switzerland, November 29, 2022 - Helsinn Group (“Helsinn”), a fully integrated global...